Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26618316 | 1.00 | ALDH1A1 (0.37) | ALDH1A1MAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL26618313 | 0.98 | KMT2A (0.38) | ALDH1A1MAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15308496 | 0.93 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL15308549 | 0.93 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL26618309 | 0.87 | EPHX1 (0.42) | ALDH1A1LMNAMAPTEPHX1 | |
| SCHEMBL27010014 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL24316182 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL23841443 | 0.77 | ALDH1A1 (0.39) | ALDH1A1MAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL81620 | 0.77 | ALDH1A1 (0.39) | ALDH1A1MAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12236665 | 0.77 | ALDH1A1 (0.39) | ALDH1A1MAPK1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | ALDH1A1 4344/4885MAPK1 2622/4885KMT2A 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.